Ionis Pharmaceuticals Inc [IONS] stock is trading at $34.46, up 6.03%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IONS shares have gain 3.76% over the last week, with a monthly amount drifted -3.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on August 02, 2024, when BMO Capital Markets downgraded its rating to a Market Perform and also revised its price target to $60 from $67. Previously, Leerink Partners upgraded its rating to Outperform on July 24, 2024, and elevated its price target to $62. Bernstein upgraded its rating to a Mkt Perform but stick to its price target of $44 on June 14, 2024. Wolfe Research upgraded its rating to a Outperform but $58 remained the price target by the analyst firm on April 10, 2024. BofA Securities upgraded its rating to Buy for this stock on January 02, 2024, and upped its price target to $62. In a note dated October 23, 2023, BofA Securities upgraded an Neutral rating on this stock and boosted its target price from $33 to $52.
Ionis Pharmaceuticals Inc [IONS] stock has fluctuated between $31.40 and $52.49 over the past year. Currently, Wall Street analysts expect the stock to reach $62.33 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $34.46 at the most recent close of the market. An investor can expect a potential return of 80.88% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Ionis Pharmaceuticals Inc [NASDAQ:IONS] reported sales of 803.56M for the trailing twelve months, which represents a drop of -7.21%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.44%, and Net Profit Margin reading is -0.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.89 and Total Capital is -0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.99 points at the first support level, and at 31.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.45, and for the 2nd resistance point, it is at 36.45.
Ratios To Look Out For
For context, Ionis Pharmaceuticals Inc’s Current Ratio is 8.91. In addition, the Quick Ratio stands at 8.82 and the Cash Ratio stands at 1.1. Considering the valuation of this stock, the price to sales ratio is 6.77, the price to book ratio is 8.21.
Transactions by insiders
Recent insider trading involved Swayze Eric, EVP Research, that happened on Jan 16 ’25 when 7154.0 shares were sold. EVP Research, Swayze Eric completed a deal on Jan 16 ’25 to sell 22.0 shares. Meanwhile, EVP, Chf Clinical Develop Ofcr Schneider Eugene sold 6523.0 shares on Jan 16 ’25.
